Corbus Pharmaceuticals Holdings, Inc. (CRBP) ended last trading session with a change of 51.28 percent. It trades at an average volume of 1.55M shares versus 12.7M shares recorded at the end of last trading session. The share price of $8.85 is at a distance of 776.24 percent from its 52-week low and down -17.9 percent versus its peak. The company has a market cap of $412.76M and currently has 46.64M shares outstanding. The share price is currently 39.73 percent versus its SMA20, 30.31 percent versus its SMA50, and 148.91 percent versus its SMA200. The stock has a weekly performance of 62.39 percent and is 436.36 percent year-to-date as of the recent close.

On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. The higher the CRISS score the greater the improvement; a CRISS score ≥ 20% (CRISS20) can be considered a medically meaningful improvement. The difference in CRISS scores between JBT-101 and placebo groups over the trial period was significant (p = 0.044). Differences in categorical levels of CRISS responses and changes from baseline in the five individual domains of the CRISS score also supported clinical benefit of JBT-101.

Novavax, Inc. (NVAX) recently recorded -2.88 percent change and currently at $1.35 is 16.38 percent away from its 52-week low and down -85.37 percent versus its peak. It has a past 5-day performance of -8.16 percent and trades at an average volume of 18.59M shares. The stock has a 1-month performance of -13.46 percent and is -83.91 percent year-to-date as of the recent close. There were about 329.29M shares outstanding which made its market cap $444.54M. The share price is currently -9.61 percent versus its SMA20, -51.44 percent versus its SMA50, and -73.88 percent versus its SMA200.

On Nov. 09, 2016 Novavax, Inc., (NVAX) announced its financial results for the third quarter and nine months ended September 30, 2016, in conjunction with its Investor and Analyst Day update.

The Company presented a restructuring plan designed to meet the following key objectives:

  • Prioritize development activities to achieve clinical data events within 2017;
  • Reduce cash burn, extend financial horizon and minimize near-term dilution; and
  • Maintain operational core competencies to execute development plans.